TruSpine Technologies Plc

Transaction in Own Shares • Dec 24, 2020

National Storage Mechanism | Additional information

RNS Number : 7520J

TruSpine Technologies PLC

24 December 2020

TruSpine Technologies plc

("TruSpine" or the "Company")

FDA approval and working capital

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces that the application for FDA clearance for its Cervi-LOK product which it expected to make by Q4 2020 has been delayed for up to three months.  The delay is a result of being unable to secure cadaver lab time and testing due to COVID-19 restrictions.  However, the Company have been able to computer model the Cervi-LOK product in situ, and this has enabled the Company to make minor modifications to the Cervi-LOK product.

These modifications should see a significant improvement to the current design and enable the Cervi-LOK product suite to be accessible to a wider range of patients once launched.

Cadaver lab time and testing has been booked for February 2021, pending further COVID-19 restrictions.

Further to the announcement on 12 November 2020, the Company continues to be in dialogue with Evrensel Capital Partners Limited ("Evrensel") and expects Evrensel's subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share to complete by 5 January 2021, providing the Company with an additional £250,000 of gross proceeds.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

Enquiries:

TruSpine Technologies Plc		Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Adviser)			Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
WH Ireland (Broker)		Tel: +44 (0)20 7220 1666
Adam Pollock
Walbrook PR (Financial PR & IR)	Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Anna Dunphy		[email protected]

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXUOOWRRKUUUAA